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ABSTRACT
Objectives We aimed to assess the association between 
multimorbidity and deprivation on short- term mortality 
among patients with diffuse large B- cell (DLBCL) and 
follicular lymphoma (FL) in England.
Setting The association of multimorbidity and 
socioeconomic deprivation on survival among patients 
diagnosed with DLBCL and FL in England between 
2005 and 2013. We linked the English population- 
based cancer registry with electronic health records 
databases and estimated adjusted mortality rate ratios 
by multimorbidity and deprivation status. Using flexible 
hazard- based regression models, we computed DLBCL 
and FL standardised mortality risk by deprivation and 
multimorbidity at 1 year.
Results Overall, 41 422 patients aged 45–99 years were 
diagnosed with DLBCL or FL in England during 2005–
2015. Most deprived patients with FL with multimorbidities 
had three times higher hazard of 1- year mortality (HR: 
3.3, CI 2.48 to 4.28, p<0.001) than least deprived 
patients without comorbidity; among DLBCL, there was 
approximately twice the hazard (HR: 1.9, CI 1.70 to 2.07, 
p<0.001).
Conclusions Multimorbidity, deprivation and their 
combination are strong and independent predictors of 
an increased short- term mortality risk among patients 
with DLBCL and FL in England. Public health measures 
targeting the reduction of multimorbidity among most 
deprived patients with DLBCL and FL are needed to reduce 
the short- term mortality gap.
INTRODUCTION
In England, non- Hodgkin’s lymphoma 
(NHL) is the sixth most commonly diag-
nosed cancer in England with an incidence 
rate of 23.2 per 100 000 people.1 Apart 
from lung cancer, survival estimates of NHL 
(79.4% survival probability at 1 year) are 
among the lowest of the six most common 
cancers.2 3 NHL encompasses a heteroge-
neous group of malignancies with diverse 
histological patterns; in addition, the most 
common NHL subtypes are diffuse large 
B- cell lymphoma (DLBCL) and follicular 
lymphoma (FL),4 patients of which show a 
large variation in survival.5 Cancer survival 
in England is lower than other European 
countries,6 but is similar when restricting to 
those surviving after 1 year:7 identifying, and 
Strengths and limitations of this study
 ► Data contain a large sample size of high- quality 
population- based clinical records with a high nation-
al coverage of information on all patients diagnosed 
with diffuse large B- cell or follicular lymphomas in 
England during 2005–2013.
 ► Population- based administrative hospital discharge 
data were used for the assessment of comorbid 
conditions, and selection bias was reduced by re-
stricting records of comorbidities to occurring be-
tween 6 and 24 months prior to the date of cancer 
diagnosis.
 ► Cumulative mortality hazard up to 1 year since can-
cer diagnosis was modelled using a flexible para-
metric modelling approach and included restricted 
cubic splines to account for non- linear effects of 
continuous variables.
 ► Regression standardisation was used to control 
for confounding of patient baseline characteris-
tics; information on lifestyle characteristics was 
unavailable.
 ► As there were missing data, we performed a sensi-
tivity analysis by comparing complete case analysis- 
based results to those after multiple imputation: the 
conclusions were consistent.
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influencing, the factors of short- term mortality could 
reduce the gap in survival.
Over the past decades, patient survival of FL has steadily 
improved and stagnated for DLBCL;3 furthermore, dispar-
ities in survival between deprivation levels remain.8 Public 
health policies have increased awareness and set targets, 
such as minimising the length of time from referral to 
treatment, to reduce the inequalities;9 however, since 
their implementation, there has been no evidence that 
the National Health Service (NHS) Cancer Plan had an 
impact on the inequalities in cancer survival.10 The depri-
vation gap in survival is still apparent, despite the NHS 
Cancer Plan and successive policies.9
Comorbidities, which refers to the presence of a long- 
term health condition additional, but unrelated, to the 
underlying cancer,11 tend to mask cancer symptoms, 
delaying cancer diagnosis and decrease survival.12 Older 
age groups and those living in more deprived areas expe-
rience more comorbidities. With a global ageing popu-
lation, the prevalence of comorbidities is expected to 
increase.13 The association between multimorbidity and 
survival is described for other cancers,14 but for DLBCL 
and FL this relationship remains unclear.
We aim to identify the association between multimor-
bidity and risk of short- term mortality among patients 
with DLBCL and FL in England. We hypothesise that 
multimorbidity and deprivation, independently and 
combined, contribute to an increased risk of death after 
DLBCL or FL diagnosis.
METHODS
Study design, participants, data and setting
We used the data from a retrospective population- based 
cohort study with patients with DLBCL and FL diagnosed 
between 1 January 2005 and 31 December 2013 and 
followed up to 31 December 2015. DLBCL and FL diag-
noses were made according to the International Classifi-
cation of Diseases for Oncology, third edition, based on 
codes C82.0- C85.915 (online supplemental table S1 shows 
the subtype categorisation). Patients entered the study 
on the date of their diagnosis and were followed up until 
death or censored at 1 year, whichever occurred first.
Data were obtained from population- based cancer 
registries within the English National Cancer Registry 
and Analysis Service (CAS)16 and linked to patient’s 
electronic health records from Hospital Episode Statis-
tics (HES). CAS contains patient and tumour variables 
including relevant dates (birth, diagnosis and vital 
status), sex, age at diagnosis, deprivation, cancer site and 
morphology. We used population- based administrative 
hospital discharge data for the assessment of comorbid 
conditions; we analysed HES data (containing comorbid 
conditions records) according to the International Clas-
sification of Diseases, 10th revision (online supplemental 
table S2), for the period 2003–2015. HES contains clin-
ical, administrative and demographic information about 
individual patients. To avoid selection bias including 
cancer- related comorbidities, we restricted retrospective 
records of comorbidities to occurring between 6 and 
24 months prior to the date of DLBCL and FL diagnosis.17
Patient and public involvement
No patient or public involvement.
Outcome, exposure and other variables
The outcome of this study was the time since diagnosis 
up to death observed within the first year after diag-
nosis of patients with DLBLC and FL (patients alive were 
censored at survival time defined with the date of last 
known vital status), the main exposures were multimor-
bidity status and deprivation. Due to data availability and 
clinical reasoning, we include as confounders age, sex 
and ethnicity. Due to the positivity assumption, and the 
chances of having a multimorbidity, we included patients 
aged above 45 years at diagnosis (figure 1). The positivity 
assumption states that there is a non- zero probability of 
receiving any level of comorbidity status for every combi-
nation of values of the independent variables among the 
patients in the population.18
Comorbidity status was classified according to the Royal 
College of Surgeons (RCS) Charlson score (an adapta-
tion of the Charlson comorbidity index19) that includes 
12 categories for comorbidities, excludes a category 
(peptic ulcer disease) and groups diseases together (eg, 
diabetes mellitus codes with or without complications 
were grouped into a single category). The score was cate-
gorised into those with none, one comorbidity (whatever 
the type) or two or more comorbidities (defined as multi-
morbidity). The score does not weight the comorbidities 
assuming that any comorbidity has the same impact on 
short- term mortality.20
Figure 1 Overlap plots for the density of predicted 
probabilities of comorbidity status among patients (n=41 422), 
aged 45–99, in England diagnosed with non- Hodgkin’s 
lymphoma during 2005–2013. Propensity score: relates 
to the predicted probability of having any comorbidity 
level as measured by a multinomial logistic regression 
model conditioning on the independent variables (ie, age 
at diagnosis, sex, deprivation level and ethnicity). DLBCL, 
diffuse large B- cell lymphoma.
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Area- level deprivation was categorised into one of five 
quintiles (fifth is most deprived). Deprivation was used 
as a proxy of individual level socioeconomic status. We 
used the Index of Multiple Deprivation21 (IMD), which is 
an area- level deprivation score based on the Lower Super 
Output Area22 (LSOA) residence of the patient at the 
time of cancer diagnosis. LSOA is a geographical location 
with a median of 1500 inhabitants.
Ethnicity due to data sparsity among ethnic minorities 
was recorded as either white or other. Route to diagnosis 
(CAS dataset), although not considered in our analysis 
because it was on the causal pathway, is included in the 
imputation models for missing data.
Statistical analysis
We described the characteristics of patients with DLBLC 
and FL using counts and proportions, and calculated ORs 
of having a lymphoma type along with Wald test p values 
(online supplemental table S3). We assessed the unad-
justed association between having multimorbidity and 
patients’ characteristics, using χ2 tests. Then, we compute 
the number of deaths, person- time at risk and unadjusted 
rates of deaths per 100 person- years and rate ratios with 
95% CIs by patients’ characteristics by DLBCL and FL 
subtypes.
The follow- up time for those who died is from the 
date of diagnosis until death, for those alive it was 
until administrative censoring at 12 months (no lost to 
follow- up before 12 months was observed). To describe 
the multimorbidity and deprivation short- term mortality 
risk among patients with DLBCL and FL, we computed 
the 1 year cumulative hazard obtained using the non- 
parametric Nelson- Aalen estimator.23 Then, we computed 
adjusted short- term mortality risk by patient characteris-
tics using a flexible parametric modelling approach to 
model the non- linear change in mortality risk over 1 year. 
We included restricted- cubic spline to model the base-
line hazard,24 with three knots located at the 25th, 50th 
and 75th percentiles of the log event times. To define 
the model, let  t be the time since DLBCL or FL diagnosis 


















where  zi  are the indicators for the three knots of the 
baseline restricted cubic splines. The model specification 
included the restricted cubic splines for the continuous 
variable age are given by  Ai  where the knots are placed 
at 1 and 6 months, deprivation, and the vector  xim  of 
categorical covariates (ie, multimorbidity, ethnicity and 
sex). Restricted cubic splines were included to minimise 
residual confounding and to account for the non- linear 
association between age and the cumulative hazard. 
From the model, we derived the cumulative incidence 
of death at 1 year by comorbidity status (ie, none, one or 
multimorbidity) standardised to the empirical distribu-
tion of age, sex, ethnicity and deprivation.25 26
We used the same modelling approach to evaluate the 
linearly combined effect of multimorbidity and derivation 
on short- term mortality, assuming the effect of multimor-
bidity is constant across levels of deprivation.27 We assume 
that both effects (multimorbidity and deprivation) are 
independently associated with the mortality rate and that 
their effect is constant and the rate is increasing linearly.
In sensitivity analysis, we evaluated the robustness of 
our results to the missing ethnicity records by utilising 
multiple imputation using chained equations (the fully 
conditional specification multiple imputation approach), 
under a missing at random assumption. We included 
route of cancer diagnosis and Ann Arbor28 cancer stage 
as partially observed auxiliary variables because these vari-
ables were predictive of the probability of missing values 
(established via exploratory analysis of the missing data 
indicators) and are predictive of the underlying values 
themselves (established from clinical and epidemiolog-
ical reasoning).29 We generated 20 imputed datasets. 
The imputation model for the partially observed variable 
(ethnicity) was defined as a logistic regression model 
including all explanatory variables in the substantive 
model, the vital status and Nelson- Aalen estimate of the 
cumulative hazard, and the auxiliary variables (route to, 
and stage at, diagnosis). We then fit the substantive model 
to each of the 20 imputed datasets and from these esti-
mates we predicted the standardised survival (using stpm2 
package), derived the cumulative hazard (−log(Survival 
probability)) for each imputed dataset and combined the 
survival probability estimates using Rubin’s rules.30
Analyses were performed in Stata V.16 (StataCorp); the 
stpm2 package was used to estimate flexible parametric 
survival models, and the standsurv command to compute 
standardised mortality risks. The mi impute command 
was used for multiple imputation and the mi estimate 
command to combine estimates.
RESULTS
Overall, 41 422 patients in England, aged from 45 to 99 
years, were diagnosed with either DLBCL or FL between 
2005 and 2013 in England. Of 14 043 patients with FL, 
among those who died within 1 year, the proportion of 
patients with multimorbidity compared with no comor-
bidity was 3.2 times higher (22.0% vs 6.9%, respectively) 
(table 1); of 27 379 patients diagnosed with DLBCL, this 
comparison was 1.6 times higher (49.7% vs 31.5%, respec-
tively). For both DLBCL and FL subtypes, the proportion 
of multimorbidity was higher among those living in more 
deprived areas. In DLBCL only, there was a higher propor-
tion of having any comorbidity among men compared 
with women (p<0.001); for FL only, this proportion was 
slightly higher among women. As expected, multimor-
bidity was more prevalent among older age groups.
Tables 2 and 3 show the person- time at risk and unad-
justed mortality rate of death for DLBLC and FL at 1 year 
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Table 1 Vital status, age, sex, deprivation level and ethnicity according to the comorbidity status among n=41 422 patients 
with non- Hodgkin’s lymphoma in England between 2005 and 2013 (27 379 diffuse large B- cell lymphoma (DLBCL) cases and 
14 043 follicular lymphoma (FL) cases)
No comorbidity N (%) Comorbidity N (%) Multimorbidity N (%) P value*
Diffuse large B- cell lymphoma (n=27 379)
Vital status at 1 year
  Alive 16 621 (68.5) 872 (56.7) 791 (50.3) <0.001
  Dead 7648 (31.5) 666 (43.3) 781 (49.7)
Sex
  Male 12 904 (53.2) 794 (51.6) 954 (60.7) <0.001
  Female 11 365 (46.8) 744 (48.4) 618 (39.3)
Age at diagnosis (years)
  45–54 2685 (11.1) 80 (5.2) 96 (6.1) <0.001
  55–64 5154 (21.2) 257 (16.7) 200 (12.7)
  65–74 7337 (30.2) 432 (28.1) 439 (27.9)
  75+ 9093 (37.5) 769 (50.0) 837 (53.2)
Deprivation
  Least deprived 5348 (22.0) 291 (18.9) 256 (16.3) <0.001
  2 5586 (23.0) 318 (20.7) 334 (21.3)
  3 5115 (21.1) 324 (21.1) 317 (20.2)
  4 4665 (19.2) 337 (21.9) 339 (21.6)
  Most deprived 3555 (14.7) 268 (17.4) 326 (20.7)
Ethnicity
  White 17 831 (95.5) 1204 (96.6) 1169 (92.6) <0.001
  Other 848 (4.5) 43 (3.5) 93 (7.4)
Follicular lymphoma (n=14 043)
Vital status at 1 year
  Alive 12 003 (93.1) 546 (87.6) 407 (78.0) <0.001
  Dead 895 (6.9) 77 (12.4) 115 (22.0)
Sex
  Male 5980 (46.4) 275 (44.1) 257 (49.2) 0.227
  Female 6918 (53.6) 348 (55.9) 265 (50.8)
Age at diagnosis (years)
  45–54 2246 (17.4) 42 (6.7) 33 (6.3) <0.001
  55–64 3769 (29.2) 140 (22.5) 82 (15.7)
  65–74 3952 (30.6) 199 (31.9) 159 (30.5)
  75+ 2931 (22.7) 242 (38.8) 248 (47.5)
Deprivation
  Least deprived 3091 (24.0) 113 (18.1) 80 (15.3) <0.001
  2 3025 (23.5) 122 (19.6) 81 (15.5)
  3 2759 (21.4) 136 (21.8) 118 (22.6)
  4 2356 (18.3) 123 (19.7) 130 (24.9)
  Most deprived 1667 (12.9) 129 (20.7) 113 (21.7)
Ethnicity
  White 9226 (95.7) 498 (96.3) 386 (92.8) 0.012
  Other 412 (4.3) 19 (3.7) 30 (7.2)
Missing values: ethnicity n(%): DLBCL=6191 (22.6%), FL=3472 (24.7%).
*Χ2 test of association between the baseline characteristic and comorbidity status.
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after diagnosis. Among patients with FL and DLBCL, 1087 
(7.7%) and 9095 (33.2%) died before 1 year, respectively 
(tables 2 and 3). Among FL, those with one comorbidity 
or multimorbidity had 1.9 (95% CI 1.46 to 2.33, p<0.001) 
or 3.5 (95% CI 2.90 to 4.27, p<0.001) times the mortality 
rate, respectively, compared with those with no comor-
bidity (table 2). Among DLBCL, those with one comor-
bidity or multimorbidity had 1.5 (95% CI 1.41 to 1.66, 
p<0.001) or 1.9 (95% CI 1.78 to 2.06, p<0.001) times the 
mortality rate, compared with no comorbidity (table 3).
The unadjusted mortality rate of death increased with 
each increase in deprivation level: those living in the most 
deprived areas had 1.5 (95% CI 1.22 to 1.82, p<0.001) 
and 1.3 (95% CI 1.22 to 1.40, p<0.001) times the mortality 
rate compared with those living in the least deprived 
areas, for FL and DLBCL, respectively.
Table 4 shows, before and after multiple imputation, 
the mortality hazard among patients with DLBCL and 
FL at 1 year adjusted for comorbidity status, sex, age, 
deprivation and ethnicity. After multiple imputation, 
patients with multimorbidity had 2.2 (CI 1.78 to 2.64, 
p<0.001) and 1.4 (CI 1.34 to 1.55, p<0.001) times the 
mortality hazard compared with those without a comor-
bidity, for FL and DLBCL, respectively. Patients in more 
deprived areas had 1.5 (CI 1.23 to 1.84, p<0.001) and 
1.3 (CI 1.21 to 1.40, p<0.001) times the mortality hazard 
compared with those living in the least deprived areas, 
for FL and DLBCL, respectively. There was evidence of a 
linear trend in mortality hazard by deprivation level for 
FL (p<0.001) and DLBCL (p<0.001). The direction and 
magnitude of the HRs after multiple imputation were 
similar to complete case analysis.
Table 5 shows the linearly combined effect14 between 
comorbidity status and deprivation on short- term 
mortality by DLBCL and FL. Overall, at 1 year since 
diagnosis, among FL (table 5), patients who were most 
deprived with multimorbidity have 3.26 (CI 2.48 to 4.28) 
times higher short- term mortality hazard than patients 
Table 2 One- year unadjusted mortality rates and rate ratios by sex, age, deprivation, ethnicity and comorbidity status among 
patients with follicular lymphoma in England between 2005 and 2015 (n=14 043; 1087 deaths at 1 year)
Deaths/person years
Mortality rate*
(95% CI) Mortality RR 95% CI P value
One- year mortality (n=1087)
Sex
  Male 526/6218.12 8.5 (7.77 to 9.21) Ref
  Female 561/7225.93 7.8 (7.15 to 8.43) 0.92 (0.82 to 1.03) 0.157
Age at diagnosis (years)†
  10- year increase – – 2.20 (2.08 to 2.34) <0.001
Age at diagnosis (years)
  45–54 46/2300.66 2.0 (1.50 to 2.67) Ref
  55–64 129/3926.24 3.3 (2.77 to 3.90) 1.64 (1.17 to 2.30) 0.004
  65–74 274/4157.52 6.6 (5.86 to 7.42) 3.30 (2.41 to 4.50) <0.001
  75+ 638/3059.62 20.9 (19.30 to 22.54) 10.43 (7.73 to 14.07) <0.001
Deprivation
  Least deprived 211/3175.55 6.7 (5.81 to 7.60) Ref
  2 227/3102.18 7.3 (6.43 to 8.33) 1.10 (0.91 to 1.33) 0.313
  3 230/2884.20 8.0 (7.01 to 9.08) 1.20 (1.00 to 1.45) 0.055
  4 240/2471.30 9.7 (8.56 to 11.02) 1.46 (1.23 to 1.76) <0.001
  Most deprived 179/1810.81 9.9 (8.54 to 11.45) 1.49 (1.22 to 1.82) <0.001
Ethnicity
  White 742/9712.99 7.6 (7.11 to 8.21) Ref
  Other 21/450.96 4.7 (3.04 to 7.14) 0.61 (0.40 to 0.94) 0.024
Comorbidity status
  None 895/12 412.44 7.5 (7.03 to 7.97) Ref
  One 77/577.89 13.3 (10.66 to 16.66) 1.85 (1.46 to 2.33) <0.001
  Multimorbidity 115/453.71 25.4 (21.11 to 30.43) 3.52 (2.90 to 4.27) <0.001
Missing values: ethnicity n (%) = 3472 (24.7%).
*Per 100 person years.
†Continuous form of age (for each 10- year increase in age).
RR, rate ratio.
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without comorbidities and least deprived. Among DLBCL 
(table 5), and for the same comparison, the short- term 
mortality hazard was 1.88 (CI 1.70 to 2.07) times higher 
at 1 year.
Figure 2 shows the unadjusted (Nelson- Aalen non- 
parametric estimate) and standardised risks of death up 
to 1 year since diagnosis for FL and DLBCL by comor-
bidity status and deprivation. Online supplemental 
table S4A,B shows results of complete case and after 
multiple imputation. Standardised to age, sex, depriva-
tion and ethnicity, the risk of death over the first year 
was consistently higher among those with multimor-
bidity compared with those with one comorbidity or 
none. For both FL and DLBCL, the unadjusted analysis 
showed that patients with multimorbidity had consis-
tently higher cumulative incidence of death compared 
with those with one comorbidity or none (log rank test 
p<0.001).
DISCUSSION
We aimed to explore the association between comorbidity 
status, and deprivation and their combination, on short- 
term mortality for patients with FL or DLBCL. We found 
that multimorbidity and deprivation and their combined 
effect are strong independent predictors of short- term 
mortality among patients with DLBCL and FL in England 
during 2005–2015.
To our knowledge, this is the first study that inves-
tigates the association between multimorbidity, and 
deprivation, on short- term mortality among patients 
with DLBCL and FL in England. Despite the scarcity of 
research within England, our findings are consistent with 
previous evidence from other countries. A Swedish study 
found that higher comorbidity status was independently 
associated with a higher risk of mortality among patients 
with DLBCL.31 Additionally, more deprived, compared 
with least deprived, patients had a higher risk of 
Table 3 One- year unadjusted mortality rates by sex, age, deprivation, ethnicity and comorbidity status among patients with 
diffuse large B- cell lymphoma in England between 2005 and 2015 (n=27 379; 9095 deaths at 1 year)
Deaths/person years
Mortality rate*
(95% CI) Mortality RR 95% CI P value
One- year mortality (n=9095)
Sex
  Male 4867/11 318.43 43.0 (41.81 to 44.23) Ref Ref Ref
  Female 4228/9784.59 43.2 (41.93 to 44.53) 1.01 (0.96 to 1.05) 0.817
Age at diagnosis (years)†
  10- year increase – – 1.50 (1.47 to 1.53) <0.001
Age at diagnosis (years)
  45–54 430/2615.81 16.4 (14.96 to 18.07) Ref Ref Ref
  55–64 1074/4937.54 21.8 (20.49 to 23.09) 1.32 (1.18 to 1.48) <0.001
  65–74 2365/6604.47 35.8 (34.39 to 37.28) 2.18 (1.97 to 2.41) <0.001
  75+ 5226/6945.19 75.2 (73.23 to 77.31) 4.58 (4.15 to 5.05) <0.001
Deprivation
  Least deprived 1765/4684.43 37.7 (35.96 to 38.48) Ref
  2 1955/4898.09 39.9 (38.18 to 41.72) 1.06 (0.99 to 1.13) 0.079
  3 1948/4424.61 44.0 (42.11 to 46.03) 1.17 (1.10 to 1.25) <0.001
  4 1908/4017.48 47.5 (45.41 to 49.67) 1.26 (1.18 to 1.35) <0.001
  Most deprived 1519/3078.40 49.3 (46.92 to 51.89) 1.31 (1.22 to 1.40) <0.001
Ethnicity
  White 6351/15 900.73 39.9 (38.97 to 40.94) Ref
  Other 270/808.61 33.4 (29.64 to 37.62) 0.84 (0.74 to 0.94) 0.004
Comorbidity status
  None 7648/19 007.45 40.2 (39.35 to 41.15) Ref
  One 666/1081.20 61.6 (57.09 to 66.46) 1.53 (1.41 to 1.66) <0.001
  Multimorbidity 781/1014.36 77.0 (71.78 to 82.59) 1.91 (1.78 to 2.06) <0.001
Missing values: ethnicity n(%) = 6,191 (22.6%).
*Per 100 person- years.
†Continuous form of age (for each 10- year increase in age).
RR, rate ratio.
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DLBCL- related mortality and there was evidence of a 
significant linear trend across the quintiles of deprivation. 
A Danish study found that higher comorbidity status was 
independently associated with shorter survival lengths 
among patients with any type of NHL (HR 1.60, CI 1.45 to 
1.75).32 However, these studies used a non- cancer specific 
comorbidity score, which underperforms (in comparison 
to cancer- specific scores) when using predictive models 
for short- term outcomes.20 These studies suggest that the 
effect of comorbidity mainly occurs prior to, and shortly 
after, cancer diagnosis. Further studies could assess the 
effect of these prognostic factors on longer term survival 
from DLBCL or FL, using deprivation- specific life tables 
to minimise the inaccuracy of expected mortality when 
life tables are not also stratified by comorbidity status.33
As the association between deprivation and NHL 
survival is not studied as widely as solid tumours, it 
was unclear whether there was an association between 
Table 4 Adjusted HRs of death (before and after multiple imputation) for all patient characteristics among patients with (A) 
follicular or (B) diffuse large B- cell lymphoma in England between 2005 and 2015
Complete case After multiple imputation
HR* 95% CI P value HR* 95% CI P value
(A) Follicular
Sex
  Male Ref Ref – Ref Ref –
  Female 1.08 0.85 to 1.38 0.540 0.84 0.74 to 0.94 <0.001
Comorbidity status
  None Ref Ref – Ref Ref –
  One 1.52 1.15 to 2.03 <0.001 1.28 1.01 to 1.61 <0.041
  Multimorbidity 2.36 1.85 to 3.02 <0.001 2.17 1.78 to 2.64 <0.001
Deprivation†
  Least Ref Ref – Ref Ref –
  2 1.03 0.70 to 1.53 0.873 1.09 0.90 to 1.31 0.378
  3 1.47 1.00 to 2.16 0.051 1.15 0.95 to 1.39 0.143
  4 1.30 0.87 to 1.94 0.200 1.44 1.19 to 1.73 <0.001
  Most 1.63 1.11 to 2.41 0.013 1.50 1.23 to 1.84 <0.001
Ethnicity
  White Ref Ref – Ref Ref –
  Other 0.49 0.27 to 0.88 0.017 0.64 0.40 to 1.01 0.053
(B) Diffuse large B- cell
Sex
  Male Ref Ref – Ref Ref –
  Female 0.91 0.84 to 0.99 0.170 0.90 0.86 to 0.93 <0.001
Comorbidity status
  None Ref Ref – Ref Ref –
  One 1.29 1.18 to 1.42 1.24 1.15 to 1.35 <0.001
  Multimorbidity 1.61 1.47 to 1.76 <0.001 1.44 1.34 to 1.55 <0.001
Deprivation†
  Least Ref Ref – Ref Ref –
  2 1.17 1.03 to 1.33 0.013 1.05 0.98 to 1.12 0.155
  3 1.15 1.01 to 1.30 0.029 1.13 1.06 to 1.20 <0.001
  4 1.25 1.11 to 1.42 <0.001 1.23 1.15 to 1.31 <0.001
  Most 1.32 1.16 to 1.51 <0.001 1.30 1.21 to 1.40 <0.001
Ethnicity
  White Ref Ref – Ref Ref –
  Other 0.93 0.77 to 1.13 0.463 1.03 0.91 to 1.16 0.678
Missing values: (A) ethnicity n(%)=3,472 (24.7%), (B) ethnicity n(%)=6,191 (22.6%).
*Adjusted for sex, comorbidity status, deprivation, ethnicity and the restricted cubic splines of age.
†Likelihood ratio test for the overall effect of deprivation (p<0.001).
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deprivation and short- term mortality for haematological 
malignancies. Previous studies have described a depri-
vation gap in survival comparing the least- deprived to 
most- deprived,8 10 34 but have not assessed the association. 
Although explored for Hodgkin’s lymphoma,35 to our 
knowledge, this is the first study to explore the association 
between deprivation and short- term mortality for NHL 
in England: our study provides evidence of a strong and 
independent association.
There are several dynamics that may explain the asso-
ciation observed in this study. First, the presence of a 
comorbidity is known to affect the timely diagnosis of 
DLBLC and FL,36 such that comorbidities presenting with 
similar symptoms to DLBLC or FL may delay the diag-
nosis and dissimilar symptoms may hasten the diagnosis. 
Moreover, the prevalence of comorbidities increases with 
age, and among older patients with DLBCL and FL this 
prevalence is consistently over 60%,37 38 which may partly 
explain the delay in diagnosis among older ages. Further 
research is needed to identify comorbidities that alter the 
timely diagnosis
Second, guidelines of lymphoma management focus on 
a single- disease standard regimen, but there is little guid-
ance on multidisease management.39 A systematic review 
found the majority of patients with a comorbidity did not 
receive the standard regimen and were allocated alter-
native, less- intense treatments.40 Cancer care could be 
improved by defining clear guidelines that recommend 
a comorbidity- specific treatment regimen and provide an 
accurate definition, and a measure, of the dose intensity.
Third, differences in access to treatments, or risk of 
adverse effects, may partly explain the multimorbidity gap 
in survival from DLBCL and FL; clinicians may abstain 
from allocating a treatment associated with a higher risk 
of adverse events because it can exacerbate the complex 
management of cancer care. Patients without comorbid-
ities, after receiving standard treatment regimens, still 
experience an increased risk of cardiovascular events.41 
A first- line standard treatment for DLBCL is a combi-
nation of chemotherapy and immunotherapies, such as 
Table 5 Linearly combined adjusted HR of comorbidity status with deprivation level on short- term mortality (after multiple 
imputation) among (A) follicular lymphoma (FL) (deaths at 1 year: n=1087) and (B) diffuse large B- cell lymphoma (DLBCL) 
(1 year: n=9095) for patients in England from 2005 to 2015
Comorbidity status
None One Multimorbidity
HR* (95% CI) HR* (95% CI) HR* (95% CI)
(A) Follicular
Deprivation
  Least deprived Ref 1.28 (1.01 to 1.61) 2.17 (1.78 to 2.64)
  2 1.09 (0.90 to 1.31) 1.39 (1.03 to 1.88) 2.36 (1.80 to 3.10)
  3 1.15 (0.95 to 1.39) 1.47 (1.09 to 1.98) 2.50 (1.91 to 3.26)
  4 1.44 (1.19 to 1.73) 1.84 (1.36 to 2.47) 3.12 (2.40 to 4.06)
  Most deprived 1.50 (1.23 to 1.84) 1.92 (1.42 to 2.59) 3.26 (2.48 to 4.28)
(B) DLBCL
Deprivation
  Least deprived Ref 1.24 (1.15 to 1.35) 1.44 (1.34 to 1.55)
  2 1.05 (0.98 to 1.12) 1.30 (1.18 to 1.44) 1.51 (1.37 to 1.67)
  3 1.13 (1.06 to 1.20) 1.40 (1.27 to 1.55) 1.63 (1.48 to 1.80)
  4 1.23 (1.15 to 1.31) 1.52 (1.38 to 1.69) 1.78 (1.61 to 1.95)
  Most deprived 1.30 (1.21 to 1.40) 1.62 (1.46 to 1.80) 1.88 (1.70 to 2.07)
*Adjusted for sex, ethnicity and the restricted cubic splines of age.
Figure 2 Risk of short- term mortality for follicular lymphoma 
(FL) (n=14 043) and diffuse large B- cell lymphoma (DLBCL) 
(n=27 379) by comorbidity status and deprivation level 
in England between 2005 and 2015 (solid: Aalen- Nelson 
approach, dash: standardised to the empirical distribution of 
age, sex and ethnicity).
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rituximab, and is known to be effective for those of an 
advanced age. Rituximab is often used in combination 
with anthracyclines (eg, doxorubicin), which is associated 
with an increase in the incidence of adverse events (eg, 
cardiotoxicity) commonly in the form of congestive heart 
failure.42
Fourth, due to the indolent nature of FL, we cannot 
rule out that the increase in short- term mortality we 
observed might be due to causes of death other than the 
cancer itself (eg, multimorbidity). Moreover, the risk of 
short- term mortality was more pronounced in FL than 
DLBCL, which may also indicate that other causes of 
death (other than the cancer) may play a larger role in 
FL than DLBCL.
Lastly, the association between deprivation and short- 
term mortality, that is not explained by patient charac-
teristics, might be explained by the association between 
deprivation and use of emergency services or population 
density,43 44 or between population density and the use 
of emergency services.45 For example, population dense 
areas may accumulate high demands that current facil-
ities of healthcare services are unable to accommodate. 
Therefore, emergency services (eg, emergency diagnostic 
route), which is associated with a late stage of cancer, may 
explain the higher mortality hazard observed among 
more deprived patients. Further research could investi-
gate the demand and availability of healthcare services in 
densely populated areas.
The strengths of this study include the large sample size 
within a database of high- quality population- based clin-
ical records with a high national coverage. We linked clin-
ical records with the HES database, which encompasses 
all patients in England with a diagnosis of DLBCL and 
FL between 2005 and 2013. The objective data sources 
provide information on patients that is gathered prospec-
tively. Furthermore, the standardised risk provides an 
interpretation of the risk of death that is averaged over 
the entire population.
Due to data availability, our study has some limitations. 
First, we did not include tumour stage, route to diagnosis 
(eg, general practitioner referral), or treatment plan; 
consequently, further research is needed to dissect the 
effects of comorbidity, stage and treatment on survival. 
Since tumour stage, route and treatment allocation are 
considered to be on the causal pathway between comor-
bidity status and short- term mortality, causal inference 
mediation analysis is required to estimate the propor-
tion of the effect of comorbidity status on survival that is 
explained by said mediators.
Second, recent research highlights the interest in 
using individual- level socioeconomic measures for 
assessing patient health outcomes in addition to area- 
level measures of deprivation.46 However, information 
on individual- level socioeconomic measures was unavail-
able, so we used only an area- level measure of socioeco-
nomic status, which encapsulates the multidimensional 
composition of a patient’s deprivation level in addition 
to the contextual level.21 Furthermore, there is better 
concordance between area- level and individual- level 
measures of education when assessing patient health 
outcomes.46 The observed deprivation level of a patient 
in our study is likely to be consistent had they been 
diagnosed at a different time; this is because depriva-
tion scores have a high concordance between updates 
(ie, IMD of 2007, 2010 and 2015).21 Our results are 
comparable to studies using this area- level measure of 
deprivation.
Third, HES data contain information on all patients 
admitted to a hospital (secondary care) in England. It 
is possible that some comorbidities were not observed 
because they were diagnosed, and treated, during 
primary care (eg, general practitioner consultations). 
However, the RCS’ comorbidity index, among other 
indices, is constructed based on the impact of the comor-
bidity on the risk of mortality; in other words, severe 
comorbidities that require hospitalisation. Comorbidi-
ties of the RCS comorbidity index are those that often 
require hospitalisation, leading to a record within HES 
data. Previous research has shown that combining 
primary care records to secondary care data identifies 
a greater proportion of comorbidity within the popula-
tion; however, the inclusion of comorbidities identified 
from primary care records does not have a large effect on 
predicted cancer survival beyond results obtained using 
secondary care data.47
Fourth, relative, or cause- specific, survival methods 
were not used in this study, which would have accounted 
for competing risks of death. Reliable information on 
the cause of death was unavailable for all patients diag-
nosed with DLBCL or FL in England in this study. Net 
survival within the relative survival setting could be an 
option; however, there are additional methodological 
issues when combining net survival with causal inference 
methods and multiple imputation. Moreover, net survival 
relies on sufficiently stratified lifetables (eg, inclusion 
of comorbid- specific conditions) to correctly account 
for the background population mortality, which are not 
currently available.33
Last, as complete case analysis may lead to selection 
bias, we performed multiple imputation under a missing 
at random assumption. We obtained the same conclusions 
under a complete case analysis and after multiple impu-
tation. Since the missing at random assumption is untest-
able,48 further work could conduct a sensitivity analysis 
to departures from the missing at random assumption, 
through techniques for imputing under a missing not at 
random assumption.49
In conclusion, multimorbidity and deprivation, 
combined and independently, are strong predictors of 
an increased risk of short- term mortality at 1 year since 
diagnosis among patients with DLBCL or FL in England. 
Therefore, public health prevention strategies are needed 
to reduce the short- term mortality gap due to socioeco-
nomic inequalities and comorbidities among patients 
with NHL.
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